Thank you for your interest in the Innovations in Pre-exposure Prophylaxis (PrEP) for Respiratory Viruses program. Since the program is looking for innovations in delivery, biodistribution, and durability of PrEP approaches, teaming collaborations between diverse sets of innovators might be needed to achieve these goals.
Teaming
If you or your organization would like to explore collaborations with other potential applicants, please complete the form below. After a short vetting process, you will be contacted be VITAL, and your information will be added to the publicly accessible list below.
Please note that by publishing the teaming profiles list, neither VITAL nor BARDA is endorsing, sponsoring, or otherwise evaluating the qualifications of the individuals or organizations included. Additionally, completing the form does not constitute an application for the PrEP funding opportunity, but rather, provides you an opportunity to partner and collaborate with other potential applicants to strengthen the quality of the submission.
Submissions to the teaming profiles list are reviewed and updated periodically.
Contact
Organization
Relevant Technology
Potential for Teaming
InDevR offers a multiplexed, microarray-based analytics platform called VaxArray. VaxArray assays can be flexibly designed to simultaneously quantify dozens of analytes in a single assay with high ease of use and rapid times to result of ~1 hour. By printing antibodies in a microarray format, we can assess relative antigen binding for initial therapeutic antibody screening applications. Alternatively, by printing recombinant antigens or peptides, we can assess antibody binding to a variety of closely-related antigens. If potential therapeutic antibodies are being delivered as LNP-mRNAs, VaxArray can also be used to assess the quantity of the in vitro expressed antibody/antibodies. InDevR has been supporting influenza, COVID, pneumococcal conjugate, and other vaccine developers and manufacturers for over 15 years with numerous off the shelf kits. In addition, we offer full custom assay development services and have delivered on over 40 custom projects. Our VaxArray influenza NA assay is being utilized as an official release assay for identity testing, and our platform software is amenable to integration in 21 CFR part 11-regulated environments.
We would like to partner with responders to this call by developing custom assays that would fill an analytical gap for their development program that would be well-addressed with an easy to use, rapid, multiplexed VaxArray platform approach.
Jubilant HollisterStier LLC, (JHS) is a leading integrated contract manufacturer of parenteral products and ophthalmics. We are able to support manufacturing of multiple formats for sterile liquid/lyophilized vials, ampoules and sterile ophthalmic solutions and ointments. Located in Spokane, Washington, and Montreal, Quebec Canada JHS provides specialized manufacturing for pharmaceutical and biopharmaceutical products and offers a full range of other support, from process qualification through commercial release with final packaging and serialization services.
As one of the recipients of the U.S. Department of Health and Human Services’ (“HHS”) investments in the Industrial Base Expansion (“IBX”) program, JHS will double the capacity of the fill-finish site in Spokane, Washington by 2024 resulting in sterile injectable production of over 110 million units per year. The capabilities and technologies included in the expansion include:
Innovators without the capability of clinical and large scale manufacturing.
